Quarterly Result13 Aug 2025, 03:03 pm
Suven Life Sciences Announces Q1 FY 2025-26 Financial Results with INR 8576.40 Million Fund Raising
AI Summary
Suven Life Sciences, a Biopharmaceutical company engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders, has announced its unaudited financial results for the quarter ended 30 June 2025. The results were reviewed by the audit committee and approved by the Board of Directors. The company has reported R&D and Operational expenses of INR 526.15 million and a fund raising of INR 8576.40 million through the issuance of convertible warrants. The company's clinical development pipeline includes SUVN-502, SUVN-G3031, SUVN-911, SUVN-D4010, and SUVN-I6107, which are at various stages of clinical studies.
Key Highlights
- Suven reported R&D and Operational expenses of INR 526.15 million for Q1 FY 2025-26.
- The company has successfully completed a fund raising program of INR 8576.40 million.
- Suven's clinical development pipeline includes five drugs at various stages of clinical studies.
- The company's drug SUVN-502 is in a phase 3 study for Agitation and Aggression in Alzheimer’s type dementias.
- SUVN-G3031 is preparing to start a Phase 3 clinical study for treatment of EDS in Narcolepsy.